Laurie Keilholz

Executive Director, Pharmaceutical Dev

Role: Executive Director, Pharmaceutical Dev at Celcuity
Location: Durham, NC, US
LinkedIn followers: 500 followers

General Business & ManagementView LinkedIn profile

About Laurie Keilholz

Pharmaceutical Scientist with over 20 years’ experience in research and development…

Experience

Executive Director, Pharmaceutical Dev
Celcuity
Mar 2024 — Present

Education

University of North Carolina at Charlotte
Bachelor's degree, Chemistry
1991 — 1995

Skills

Pharmaceutical Industry
Clinical Development
Drug Development
Fda
Validation
Biotechnology
Clinical Research
Glp
Cmc
Sop
Analytical Chemistry
Method Development
Clinical Trials
Bioanalysis
Vendor Management
Gmp
Drug Discovery
Project Management
Life Sciences
CRO
Infectious Diseases
Pre-Clinical Studies
Regulatory Submissions
Mass Spectrometry
Formulation
Analytical Method Validation
Hplc
Pharmaceutical Sciences
Drug Delivery
Research
Uv
Karl Fisher
Microsoft Office
Research and Development (R&D)
High-Performance Liquid Chromatography (Hplc)
Good Laboratory Practice (Glp)
U.s. Food and Drug Administration (Fda)
Standard Operating Procedure (Sop)
CRO Management

Contact information

Verified work emails, personal emails, and direct dials — unlocked in one click.

Work email
•••••@celcuity.com
Personal email
•••••@•••••.com
Direct dial
+•• ••• ••• ••••

Unlock verified contacts

Free to start · No credit card required

Current company

Celcuity

Biotechnology · 256 employees · Minneapolis, Minnesota, United States

Celcuity is a clinical-stage, publicly traded biotechnology company seeking to extend the lives of cancer patients through the development of targeted therapies for the treatment of multiple solid tumor indications. The company was founded to develop a better way to treat the cellular drivers of tumor growth. Our lead therapeutic candidate, gedatolisib, is an intravenously administered, potential first-in-class PI3K/AKT/mTOR (PAM) pathway inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. Gedatolisib phase 3 clinical development programs are focused on the treatment of patients with HR+/HER2- ABC in the 1L and 2L settings. A Phase 1b/2 clinical trial evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is on-going. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at www.celcuity.com

celcuity.com

Find verified contacts for anyone on LinkedIn

Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.

Start for free See how it works

Free plan included · No credit card required

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.